Skip to main content

Table 1 Demographic and clinical data

From: Pharmacokinetics of meropenem in septic patients on sustained low-efficiency dialysis: a population pharmacokinetic study

Variable Mean (SD), n (%) or median [IQR] Range
Age, years 66 [51–74] 37–78
Male gender 14 (74%) N/A
Height, m 1.73 [1.68–1.82] 1.55–1.90
Weight, kg 81 [76–90] 70–183
BMI, kg/m2 28 [26–31] 22–57
SOFA score on ICU admission 10 [9–13] 2–20
SAPS II on ICU admission 46 [34–50] 16–76
SOFA score on the first day of sampling 11 [9–13] 5–16
Mechanical Ventilation on sampling day 1 27 (58%) N/A
Use of Vasopressors on sampling day 1 17 (89%) N/A
Procalcitonin [μg/L] on sampling day 1 1.48 [0.72–3.02] 0.28–21.4
C-reactive protein on sampling day 1 101 [51–162] 16–267
Serum creatinine [mg/dL]* on sampling day 1 2.6 [1.7–4] 0.8–9.1
Serum albumin conc. [g/L] on sampling day 1 15.5 (3.7) 10–21
Meropenem trough concentration [mg/L] 28.9 [21.6–36.9] 10.2–95.8
SLED duration [min] 315 [275–354] 80–470
Residual diuresis [mL/d] 0 [0-80] 0–360
Blood/dialysate flow [mL/min] 250 [208–278] 170–350
Ultrafiltration rate [mL/h] 500 [400–597] 50–1000
ICU length of stay [days] 36 [23–79] 8–264
Death 9 (47%) N/A
  1. BMI body mass index, ICU intensive care unit, IQR interquartile range, N/A not applicable, SD standard deviation, SLED sustained low-efficiency dialysis, SAPS II Simplified Acute Physiology Score; SOFA sequential organ failure assessment, *Data of the first day of inclusion in study, possibly affected by previous SLED or CRRT sessions